Product nameAnti-ATM (phospho S1981) antibody [EP1890Y]
See all ATM primary antibodies
DescriptionRabbit monoclonal [EP1890Y] to ATM (phospho S1981)
Tested applicationsSuitable for: Dot blot, WB, IHC-P, IP, Flow Cytmore details
Unsuitable for: ICC/IF
Species reactivityReacts with: Human
Synthetic peptide within Human ATM (phospho S1981). The exact sequence is proprietary.
(Peptide available as
- WB: HEK-293 cell lysate treated with doxorubicin. IHC-P: Human gastric carcinoma, breast carcinoma, tonsil, cervical carcinoma, hepatocellular carcinoma and endometrial carcinoma tissues and mouse endometrium tissue. IP: HEK-293 cell lysate treated with doxorubicin. FC: HepG2 cells
A trial size is available to purchase for this antibody.
Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab81292 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/50000. Detects a band of approximately 370 kDa (predicted molecular weight: 351 kDa).Can be blocked with Human ATM peptide (ab235690).
We highly recommend using a positive control such as HEK293 cells treated with 10uM doxorubicin for 24 hours.
|IHC-P||1/70 - 1/250. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.|
|IP||1/30 - 1/40.
FunctionSerine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. May function as a tumor suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9 and DCLRE1C. May play a role in vesicle and/or protein transport. Could play a role in T-cell development, gonad and neurological function. Plays a role in replication-dependent histone mRNA degradation. Binds DNA ends.
Tissue specificityFound in pancreas, kidney, skeletal muscle, liver, lung, placenta, brain, heart, spleen, thymus, testis, ovary, small intestine, colon and leukocytes.
Involvement in diseaseDefects in ATM are the cause of ataxia telangiectasia (AT) [MIM:208900]; also known as Louis-Bar syndrome, which includes four complementation groups: A, C, D and E. This rare recessive disorder is characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. AT patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.
Note=Defects in ATM contribute to T-cell acute lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). TPLL is characterized by a high white blood cell count, with a predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, skin lesions and serous effusion. The clinical course is highly aggressive, with poor response to chemotherapy and short survival time. TPLL occurs both in adults as a sporadic disease and in younger AT patients.
Note=Defects in ATM contribute to B-cell non-Hodgkin lymphomas (BNHL), including mantle cell lymphoma (MCL).
Note=Defects in ATM contribute to B-cell chronic lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in the elderly. It is characterized by the accumulation of mature CD5+ B lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure.
Sequence similaritiesBelongs to the PI3/PI4-kinase family. ATM subfamily.
Contains 1 FAT domain.
Contains 1 FATC domain.
Contains 1 PI3K/PI4K domain.
DomainThe FATC domain is required for interaction with KAT5.
modificationsPhosphorylated by NUAK1/ARK5. Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA damage-mediated activation of the kinase.
Acetylation, on DNA damage, is required for activation of the kinase activity, dimer-monomer transition, and subsequent autophosphorylation on Ser-1981. Acetylated in vitro by KAT5/TIP60.
Cellular localizationNucleus. Cytoplasmic vesicle. Primarily nuclear. Found also in endocytic vesicles in association with beta-adaptin.
- Information by UniProt
- A-T mutated antibody
- A-T mutated homolog antibody
- AT mutated antibody
All lanes : Anti-ATM (phospho S1981) antibody [EP1890Y] (ab81292) at 1/50000 dilution (purified)
Lane 1 : HEK-293 (Human epithelial cell line from embryonic kidney) cell lysate, untreated
Lane 2 : HEK-293 cell lysate, treated with Doxorubicin
Lysates/proteins at 10 µg per lane.
All lanes : Peroxidase conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution
Predicted band size: 351 kDa
Observed band size: 370 kDa why is the actual band size different from the predicted?
Blocking and dilution buffer: 5% NFDM/TBST.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human hepatocellular carcinoma tissue labelling ATM (phospho S1981) with purified ab81292 at 1/70. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, an HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500).
Negative control using PBS instead of primary antibody.
Counterstained with hematoxylin.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human breast carcinoma tissue labeling ATM with unpurified ab81292.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human tonsil tissue labeling ATM with unpurified ab81292.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human cervical carcinoma tissue labeling ATM with unpurified ab81292.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human endometrial carcinoma tissue labeling ATM with unpurified ab81292.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human gastric carcinoma tissue labeling ATM with unpurified ab81292 at a 1/100 dilution.
Flow Cytometry analysis of HepG2 (Human hepatocellular carcinoma) cells labeling ATM (phospho S1981) with purified ab81292 at 1/60 dilution (10 µg/mL) (red).
Cells were fixed with 4% paraformaldehyde and permeabilized with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor®488) at 1/2000 dilution was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) was used as the unlabeled control.
ATM was immunoprecipitated from HEK-293 (Human embryonic kidney epithelial cell) treated with Doxorubicin whole cell lysate with ab81292 at 1/30 dilution (5 µg in 1 mg lysates). Western blot was performed from the immunoprecipitate using ab81292 at 1/2000 dilution. An anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG was used as secondary antibody at 1/1500 dilution.
Lane 1: HEK-293 treated with Doxorubicin whole cell lysate 10 µg (Input).
Lane 2: ab81292 IP in HEK-293 treated with Doxorubicin whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab81292 in HEK-293 treated with Doxorubicin whole cell lysate.
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
Dot blot analysis of ATM peptides using ab81292 at 1/000 dilution followed by Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated secondary antibody (ab97051) at 1/100,000 dilution.
Blocking and diluting buffer was 5% NFDM/TBST, exposure time 3 minutes.
Lane 1: ATM (pS1981) phospho peptide
Lane 2: ATM non-phospho peptide
Lane 3: ATM (pS428) phospho peptide
This product has been referenced in:
- Wang Y et al. Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells. JCI Insight 3:N/A (2018). Read more (PubMed: 29415883) »
- Collin G et al. Transcriptional repression of DNA repair genes is a hallmark and a cause of cellular senescence. Cell Death Dis 9:259 (2018). Read more (PubMed: 29449545) »